The invention refers to 
medicine, in particular to hepatology and 
virology, and can be used for treatment, including complete 
recovery, of patients with 
viral hepatitis C, including its chronic form. This invention provides a remedy for treating 
viral hepatitis C, that is, apoprotein 
lactoferrin in a monomeric form. This invention also refers to a pharmaceutical composition for treating 
viral hepatitis C that contains a therapeutically effective amount of apoprotein 
lactoferrin in a monomeric form and a pharmaceutically acceptable vehicle, filler or 
excipient. This invention also refers to a pharmaceutical composition for treating viral 
hepatitis C that includes administration of apoprotein 
lactoferrin in a monomeric form and to using apoprotein lactoferrin in a monomeric form for manufacturing a medication for treating viral 
hepatitis C. The treatment method of this invention allows to prevent 
virus viremia completely as a result of two or three weeks treatment, to prevent destruction of hepatocytes, affected with 
hepatitis C 
virus, together with the emission of additional number of viruses to the 
blood circulation system and to end the existence of the affected with 
virus hepatocytes with 
apoptosis, thus, preventing the development of hepatosis, 
cirrhosis and oncological damage to the liver, being the 
terminal stage of the main 
disease development.